TEMOZOLOMIDE IN THE TREATMENT OF ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE

这项试验的目的是：1)确定 替莫唑胺定义为6个月无进展生存期和安全性 替莫唑胺口服，每日一次，连用五天 间变性患者每28天重复一次的治疗 星形细胞瘤最初复发。2)描述与健康相关的质量 所有病人的生活。3)评估基于群体的药代动力学 在接受替莫唑胺的患者中。4)评估所有人的总体生存 病人。 在过去的一年里只有一名患者参加了试验 由于缺乏应计利润而关闭。

The objectives of this trial are: 1) To determine the efficacy of temozolomide defined as progression-free survival at 6 months and safety of temozolomide when administered orally, once a day for five days repeated every 28 days in the treatment of patients with anaplastic astrocytoma at first relapse. 2) To describe the health-related quality of life of all patients. 3) To assess population-based pharmacokinetics in patients receiving temozolomide. 4) To assess overall survival for all patients. There was one patient enrolled in the past year and the trial has been closed due to lack of accrual.